Uptravi
(Selexipag)ApprovedSmall molecule
Johnson & JohnsonSelexipag is used to treat pulmonary arterial hypertension, a condition where blood vessels in the lungs become narrowed, making it harder for the heart to pump blood through them. It helps relax these blood vessels and improve blood flow.[2] Uptravi is currently approved and in use across 4 indications[4].[1]
Uptravi is one of 95 small molecule programs targeting Idiopathic Pulmonary Arterial Hypertension. It is currently in Approved.
4
Indications
25
Total Trials
5
Active Trials
94
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
53 competitors in Pulmonary Arterial Hypertension
#DrugCompanyPhaseTrials
1Letairis
GileadApproved
Tracleer
Johnson & JohnsonApproved
Winrevair
Merck & Co.Approved
Opsumit
Johnson & JohnsonApproved
Remodulin
United TherapeuticsApproved
Cialis
Eli LillyApproved
Adempas
BayerApproved
Viagra
VViatris Specialty LLC
Approved
Aldactone
PfizerApproved
Diamox
TevaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Arterial Hypertension9 trials
Show 6 more trials
A Multicentre Randomised Cross-over Trial of Disease Specific Therapy in Patients With Pulmonary Arterial Hypertension (PAH) Implanted With Pulmonary Artery Pressure and Cardiac Rhythm Monitoring Devices (CardioMEMS/ConfirmRx)
Active, not recruiting·SSheffield Teaching Hospitals NHS Foundation Trust·Approved·NCT05825417·70 enrolled
ART2 trials
Hypertension, Pulmonary2 trials
Non-healing Wound1 trial
10 more indications
Interaction1 trial
Cardiac Repolarization1 trial
Concentration1 trial
TED1 trial
Pulmonary Hypertension1 trial
Systemic Sclerosis1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Dec 21, 2015
UPTRAVI
NDA NDA207947
Jul 29, 2021
UPTRAVI
NDA NDA214275
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Uptravi drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Selexipag. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Prostanoid IP Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Apr 30, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7205302Oct 31, 2026
7205302*PEDApr 30, 2027
9173881Aug 12, 2029
9173881*PEDFeb 12, 2030
9284280Jun 25, 2030
7 more patents
8791122Aug 1, 2030
9284280*PEDDec 25, 2030
8791122*PEDFeb 1, 2031
10828298Dec 1, 2036
10821108Dec 1, 2036
10828298*PEDJun 1, 2037
10821108*PEDJun 1, 2037